Henlez provides biologic solutions to manage recurrent and follicular skin disorders.
Henlez has raised $988K in total funding. The most recent round was Seed. The last funding was announced in October 2022.
Henlez's investors include EIR Ventures, Karolinska.
Henlez is headquartered in Copenhagen, Denmark.
Henlez provides biologic solutions to manage recurrent and follicular skin disorders.
Henlez is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Henlez — Funding & Investors." VCBacked, October 24, 2022, https://www.vcbacked.co/company/henlez. Accessed August 14, 2026.
VCBacked. (2022). Henlez — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/henlez
{{cite web |title=Henlez — Funding & Investors |url=https://www.vcbacked.co/company/henlez |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated